Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002052113-25-002028
Filing Date
2025-04-30
Accepted
2025-04-30 13:14:26
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6005
2 PowerOfAttorney.txt EX-24 2753
3 Item_7.txt EX-99 492
  Complete submission text file 0002052113-25-002028.txt   11136
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Subject) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88552 | Film No.: 25893221
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)